Brief: Hansa Biopharma, Medison Pharma Sign Commercialization Partnership For Central Eastern Europe, Israel
07/12/2021 07:05
Dec 7 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA AND MEDISON PHARMA ANNOUNCE MULTIREGIONAL COMMERCIALIZATION PARTNERSHIP
FOR
HANSA'S DESENSITIZATION TREATMENT FOR KIDNEY TRANSPLANT IN CENTRAL EASTERN EUROPE AND ISRAEL
* MARKETING AUTHORIZATION APPLICATION FOR DESENSITIZATION TREATMENT IN KIDNEY TRANSPLANT
FILED IN
ISRAEL EARLIER THIS YEA
* PARTNERSHIP COVERS CROATIA, HUNGARY, POLAND AND SLOVENIA IN ADDITION TO ISRAEL.
Source text for Eikon: ID:nWkryMpYb
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS